Skip to main content
SpringerLink
Log in

ICE II trial results in elderly patients with breast cancer

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The ICE II (Investigational Chemotherapy for Elderly patients II) trial was planned as a sequential phase II/III study. However, the phase III portion of the trial was not initiated due to slow accrual and limited financial support (despite approval for continuation by the independent Data Monitoring Committee).

Reference

  • von Minckwitz G, et al. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer : [10 pages], 25 Jun 2015. Available from: URL: http://dx.doi.org/10.1002/cncr.29506

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICE II trial results in elderly patients with breast cancer. Reactions Weekly 1560, 12 (2015). https://doi.org/10.1007/s40278-015-3384-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-3384-6

Search

Navigation